```
=> b reg
FILE 'REGISTRY' ENTERED AT 13:04:01 ON 05 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 FEB 2010  HIGHEST RN 1204649-95-5
DICTIONARY FILE UPDATES:   4 FEB 2010  HIGHEST RN 1204649-95-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l10
L7              STR

Cy^ Hy^ Hy
 1   2  3


NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X6 C  X1 N  AT   1
ECOUNT  IS E3 C  E2 N  AT   2
ECOUNT  IS E4 C  E1 O  AT   3

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   3

STEREO ATTRIBUTES: NONE
L8        59880 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  OC4/ES AND N2C3/ES
                AND (C6 OR NC5)/ES
L10       10904 SEA FILE=REGISTRY SUB=L8 SSS FUL L7

100.0% PROCESSED   59880 ITERATIONS                      10904 ANSWERS
SEARCH TIME: 00.00.05



=> d que sta l25
L7              STR

Cy^ Hy^ Hy
 1   2  3


NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X6 C  X1 N  AT   1
ECOUNT  IS E3 C  E2 N  AT   2
ECOUNT  IS E4 C  E1 O  AT   3

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   3

STEREO ATTRIBUTES: NONE
L8        59880 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  OC4/ES AND N2C3/ES
                AND (C6 OR NC5)/ES
L10       10904 SEA FILE=REGISTRY SUB=L8 SSS FUL L7
```

L23 STR



REP G1=(0-7) C
VAR G2=8/9/10
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS X6 C X1 N AT 1
ECOUNT IS E4 C E1 O AT 12

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE
L25 496 SEA FILE=REGISTRY SUB=L10 SSS FUL L23

100.0% PROCESSED 10904 ITERATIONS 496 ANSWERS
SEARCH TIME: 00.00.01

=> b zcap
FILE 'ZCAPLUS' ENTERED AT 13:04:11 ON 05 FEB 2010

FILE COVERS 1907 - 5 Feb 2010 VOL 152 ISS 7
FILE LAST UPDATED: 4 Feb 2010 (20100204/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

ZCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitrn fhitstr l29 tot

L29 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2004:841775 ZCAPLUS
DN 141:350163
TI Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists
IN Schiemann, Kai; Ackermann, Karl-August; Arlt, Michael; Finsinger, Dirk; Schadt, Oliver; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PA Merck Patent GmbH, Germany
SO Ger. Offen., 102 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE----10315572	A1	20041014	2003DE-100015572	20030405
AU--2004228120	A1	20041021	2004AU-000228120	20040308
CA-----2521201	A1	20041021	2004CA-002521201	20040308
WO--2004089931	A1	20041021	2004WO-EP0002353	20040308
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP-----1626967	A1	20060222	2004EP-000718277	20040308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR--2004009164	A	20060411	2004BR-000009164	20040308
CN-----1768051	A	20060503	2004CN-080008572	20040308
JP---2006522035	T	20060928	2006JP-000504584	20040308
US--20060264419	A1	20061123	2005US-000552065	20051005
ZA---2005008948	A	20070328	2005ZA-000008948	20051104
PRAI 2003DE-100015572	A	20030405		
2004WO-EP0002353	W	20040308		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:350163
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Preparation of title compds. I [X = CH, N; R1 = H, halo, (CH2)nHet, etc.; R2 = (CH2)nHet, (CH2)nAr, cycloalkyl, etc.; R3, R4 = H, (CH2)nCOHet, CHO, etc.; n = 0-5; Ar = (un)substituted Ph; Het = (un)substituted monoarom., bicyclic-heterocycle] and their pharmaceutically acceptable salts were prepared For example, sodium triacetoxyborohydride meditated reductive amination of 1-methyl-piperazine and aldehyde II, e.g., prepared from 2-fluoro-α,γ-dioxo-benzenebutanoic Et ester in 4-steps, afforded the dihydrochloride salt of arylpyrazole III. In 5-HT2A receptor binding assays, 167-examples of compds. I exhibited IC50 values ranging from 0.015-4.7x10-7M. Compds. I are claimed suitable as ligands of 5-HT receptors.
IT **770739-06-5** **770739-09-8** **770739-77-0**
RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)
IT **770739-73-6P** **770739-98-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)

L29 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2004:841772 ZCAPLUS
DN 141:332186
TI Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists.
IN Schadt, Oliver; Arlt, Michael; Finsinger, Dirk; Schiemann, Kai; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PA Merck Patent GmbH, Germany
SO Ger. Offen., 78 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE----10315569	A1	20041014	2003DE-100015569	20030405
AU--2004228124	A1	20041021	2004AU-000228124	20040310
CA-----2521227	A1	20041021	2004CA-002521227	20040310
WO--2004089932	A1	20041021	2004WO-EP0002453	20040310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP-----1611122	A1	20060104	2004EP-000718926	20040310
EP-----1611122	B1	20070613		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR--2004008986	A	20060328	2004BR-000008986	20040310
CN-----1768052	A	20060503	2004CN-080008603	20040310
JP---2006522039	T	20060928	2006JP-000504620	20040310
AT------364601	T	20070715	2004AT-000718926	20040310
ES-----2287710	T3	20071216	2004ES-000718926	20040310
US--20070010531	A1	20070111	2005US-000552064	20051005
ZA---2005008923	A	20070228	2005ZA-000008923	20051103
PRAI 2003DE-100015569	A	20030405		
2004WO-EP0002453	W	20040310		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:332186
GI



I

AB Title compds. [I; R1 = H, A, halo, (CH2)nAr, cycloalkyl, CF3, NO2, cyano, C(NH)NOH, OCF3; R2 = (CH2)nHet, (CH2)nAr, cycloalkyl, CF3; R3, R4 = H, (CH2)nCO2R5, (CH2)nCOHet, CHO, (CH2)nOR5, (CH2)nHet, CH:NOA, etc.; R5 = H, A; A = alkyl, alkoxy, alkenyl, alkoxyalkyl; Ar = (substituted) Ph; Het = (aromatic) mono- or bicyclic heterocyclyl, heteroatom-containing organic residue; X = N, CH; with provisos], were prepared Thus, [1-(4'-fluorobiphen-4-yl)-5-furan-2-yl-1H-pyrazol-4-ylmethyl]methyl(1-methylpyrrolidin-3-yl)amine showed 5-HT2A activity with IC50 = 5.14E-10.
IT **1054281-99-0** **1054282-00-6** **1054282-02-8**
1054282-09-5 **1054282-16-4** **1054282-17-5**
1054282-18-6 **1054282-19-7** **1054282-20-0**
1054282-35-7 **1054282-36-8** **1054282-37-9**
1054282-38-0 **1054282-39-1** **1054282-63-1**
1054282-65-3 **1054282-66-4** **1054282-70-0**
1054282-71-1 **1054282-77-7** **1054282-97-1**
1054282-98-2 **1054282-99-3** **1054283-00-9**

L29 ANSWER 1 OF 2 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
IT **770739-06-5**
RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)
RN 770739-06-5 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-(4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L29 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

1054283-01-0	**1054283-19-0**	**1054283-20-3**
1054283-23-6	**1054283-24-7**	**1054283-37-2**
1054283-38-3	**1054283-39-4**	**1054283-50-9**
1054283-51-0	**1054283-53-2**	**1054283-59-8**
1054283-60-1	**1054283-61-2**	**1054283-62-3**
1054283-63-4	**1054283-84-9**	**1054283-85-0**
1054283-86-1	**1054283-89-4**	**1054283-91-8**
1054283-92-9	**1054283-93-0**	**1054283-94-1**
1054283-95-2	**1054284-10-4**	**1054284-38-6**
1054284-39-7	**1054284-42-2**	**1054284-43-3**
1054284-44-4	**1054284-45-5**	**1054284-64-8**
1054284-65-9	**1054284-74-0**	**1054284-75-1**
1054284-76-2	**1054284-77-3**	**1054284-78-4**
1054284-86-4	**1054284-87-5**	**1054284-94-4**
1054285-11-8	**1054285-13-0**	**1054285-14-1**
1054285-49-2	**1054285-50-5**	**1054285-67-4**
1054285-68-5	**1054285-69-6**	**1054285-70-9**
1054285-71-0	**1054285-82-3**	**1054285-83-4**
1054285-95-5	**1054285-97-0**	**1054285-98-1**
1054285-99-2	**1054286-00-8**	**1054286-30-4**
1054286-33-7	**1054286-34-8**	**1054286-36-0**
1054286-37-1	**1054286-45-1**	**1054286-46-2**
1054286-47-3	**1054286-48-4**	**1054286-73-5**
1054286-74-6	**1054286-75-7**	**1054286-76-8**
1054286-77-9		

RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists.)

IT **380682-94-8**	**770739-06-5**	**770739-07-6**
770739-08-7	**770739-09-8**	**770739-10-1**
770739-11-2	**770739-12-3**	**770739-13-4**
770739-14-5	**770739-15-6**	**770739-16-7**
770739-17-8	**770739-18-9**	**770739-19-0**
770739-20-3	**770739-21-4**	**770739-22-5**
770739-23-6	**770739-24-7**	**770739-26-9**
770739-27-0	**770739-28-1**	**770739-29-2**
770739-30-5	**770739-33-8**	**770739-34-9**
770739-35-0	**770739-36-1**	**770739-37-2**
770739-38-3	**770739-40-7**	**770739-42-9**
770739-43-0	**770739-44-1**	**770739-45-2**
770739-46-3	**770739-47-4**	**770739-48-5**
770739-51-0	**770739-54-3**	**770739-55-4**
770739-56-5	**770739-57-6**	**770739-58-7**
770739-59-8	**770739-61-2**	**770739-64-5**
770739-65-6	**770739-67-8**	**770739-68-9**
770739-69-0	**770739-70-3**	**770739-73-6**
770739-75-8	**770739-76-9**	**770739-77-0**
770739-78-1	**770739-79-2**	**770739-80-5**
770739-82-7	**770739-83-8**	**770739-85-0**
770739-86-1	**770739-88-3**	**770739-89-4**
770739-90-7	**770739-91-8**	**770739-94-1**
770739-95-2	**770739-96-3**	**770739-98-5**
770740-02-8	**770740-04-0**	**770740-05-1**
770740-06-2	**770740-08-4**	**770740-10-8**
770740-11-9	**770740-14-2**	**770740-15-3**
770740-18-6	**770740-19-7**	**770740-25-5**
770740-27-7	**770740-28-8**	**770740-29-9**
770740-30-2	**770740-34-6**	**770740-37-9**
770740-39-1	**770740-40-4**	**770740-42-6**
770740-43-7	**770740-44-8**	**770740-47-1**
770740-48-2	**770740-50-6**	**770740-52-8**
770740-59-5	**770740-60-8**	**770740-63-1**
770740-64-2	**770740-65-3**	**770740-67-5**
770740-69-7	**770740-70-0**	**771525-15-6**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists)
IT **1054281-99-0**
RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists.)
RN 1054281-99-0 ZCAPLUS
CN 1H-Pyrazole-4-ethanol, 1-(3'-fluoro-4'-methoxy[1,1'-biphenyl]-4-yl)-5-(2-

L29 ANSWER 2 OF 2 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
furanyl]- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

=> d bib abs hitstr l34 tot

L34 ANSWER 1 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2005:497502 ZCAPLUS
DN 143:53440
TI Substituted benzoimidazole compounds as transcription factor-modulating compounds useful as anti-infectives
IN Levy, Stuart B.; Alekshun, Michael N.; Podlogar, Brent L.; Ohemeng, Kwasi; Verma, Atul K.; Warchol, Tadeusz; Bhatia, Beena; Bowser, Todd; Grier, Mark
PA Paratek Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 463 pp., Cont.-in-part of U.S. Ser. No. 139,591.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US-20050124678	A1	20050609	2003US-000700661	20031103 <--
	US-----7405235	B2	20080729		
	CA-----2445515	A1	20021104	2002CA-002445515	20020506 <--
	AU--2002367953	A1	20040106	2002AU-000367953	20020506 <--
	AU--2002367953	B2	20080717		
	EP-----1524974	A2	20050427	2002EP-000807554	20020506 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP--2005519998	T	20050707	2004JP-000515557	20020506 <--
	US-20030229065	A1	20031211	2002US-000139591	20020814 <--
	US-20040106553	A1	20040603	2003US-000602562	20030624 <--
	US-20090131401	A1	20090521	2008US-000069723	20080212 <--
	AU--2008203017	A1	20080731	2008AU-000203017	20080708 <--
PRAI	2001US-00288660P	P	20010504	<--	
	2002US-000139591	A2	20020814	<--	
	2002US-00423319P	P	20021101	<--	
	2002US-00425916P	P	20021113	<--	
	2002AU-000367953	A3	20020506	<--	
	2002WO-US0014255	W	20020506	<--	
	2002US-00391345P	P	20020624	<--	
	2002US-00421218P	P	20021025	<--	
	2002US-00429142P	P	20021126	<--	
	2003US-00458935P	P	20030331	<--	
	2003US-000700661	A3	20031103	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 143:53440
AB Substituted benzoimidazole compds. useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compds., as well as pharmaceutical prepns. thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms. The present invention identifies microbial transcription factors, especially transcription factors of the AraC-XylS family, as virulence factors in microbes and shows that inhibition of these factors reduces the virulence of microbial cells. Because these transcription factors control virulence, rather than essential cellular processes, the development of resistance is much less likely.
IT **634189-97-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)
RN 634189-97-2 ZCAPLUS
CN Morpholine, 4-[[4-[2-[5-(2-furanyl)-4,5-dihydro-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]-4-thiazolyl]phenyl]sulfonyl]-, hydrobromide (1:1) (CA INDEX NAME)

L34 ANSWER 1 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HBr

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2004:841776 ZCAPLUS
DN 141:350164
TI Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists
IN Schiemann, Kai; Schadt, Oliver; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PA Merck Patent GmbH, Germany
SO Ger. Offen., 17 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE----10315573	A1	20041014	2003DE-100015573	20030405 <--
	AU--2004228121	A1	20041021	2004AU-000228121	20040308 <--
	CA-----2521202	A1	20041021	2004CA-002521202	20040308 <--
	WO--2004089910	A1	20041021	2004WO-EP0002354	20040308 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP-----1611107	A1	20060104	2004EP-000718264	20040308 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR--2004009002	A	20060328	2004BR-000009002	20040308 <--
	CN-----1768043	A	20060503	2004CN-080008629	20040308 <--
	JP--2006522036	T	20060928	2006JP-000504585	20040308 <--
	ZA--2005008951	A	20070328	2005ZA-000008951	20051104 <--
	US-20070105871	A1	20070510	2006US-000551998	20061005 <--
	US-----7566709	B2	20090728		
PRAI	2003DE-100015573	A	20030405	<--	
	2004WO-EP0002354	W	20040308	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:350164
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Preparation of title compds. I (X = CH, N; Y = (CH2)mQ; m = 1-3; Q = NR3R4, Het; R1, R2 = H, halo, (CH2)nHet, etc.; n = 0-5; R3, R4 = H, (CH2)nHet, cycloalkyl, etc.; n = 0-5; R5 = A, Ar, Het; A = (un)substituted alkyl, alkoxy, alkenyl, etc.; Ar = (un)substituted aromatic; Het = organic heteroatom (sic)] and their pharmaceutically acceptable salts were prepared For example, palladium mediated coupling of 4-fluorobenzeneboronic acid and phenylbromide II, e.g., prepared from 2-furylethanone in 3-steps, afforded arylpyrazole III. In 5-HT2A receptor binding assays, compds. I exhibited nanomolar affinity (sic). Compds. I are claimed useful as ligands of 5-HT receptors.
IT **1076054-92-6** **1076054-93-7** **1076054-95-9**
1076054-96-0 **1076054-97-1** **1076054-98-2**
1076055-01-0 **1076055-02-1** **1076055-03-2**
1076055-04-3 **1076055-05-4** **1076055-06-5**
1076055-07-6 **1076055-08-7** **1076055-10-1**
1076055-12-3 **1076055-13-4** **1076055-14-5**
1076055-18-9 **1076055-22-5** **1076055-24-7**
1076055-25-8 **1076055-26-9** **1076055-28-1**
1076055-29-2 **1076055-30-5** **1076055-31-6**
1076055-35-0 **1076055-36-1** **1076055-37-2**
1076055-39-4
RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)
RN 1076054-92-6 ZCAPLUS

L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
CN Morpholine, 4-[[3-(2-furanyl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1076054-93-7 ZCAPLUS
CN Piperazine, 1-[[3-(2-furanyl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1076054-95-9 ZCAPLUS
CN Ethanol, 2-[[[1-[4-(2,3-dihydro-1,4-benzodioxin-6-yl]phenyl]-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]amino]- (CA INDEX NAME)



HO—CH2—CH2—NH—CH2

RN 1076054-96-0 ZCAPLUS
CN Piperazine, 1-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1076054-97-1 ZCAPLUS
CN 1H-1,4-Diazepine, 1-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]hexahydro-4-methyl- (CA INDEX NAME)



RN 1076054-98-2 ZCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[3-(2-furanyl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)-1H-pyrazol-4-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1076055-01-0 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[3-(2-furanyl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1076055-02-1 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[1-(3'-fluoro[1,1'-biphenyl]-4-yl]-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1076055-03-2 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, N,N-diethyl-1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)- (CA INDEX NAME)



RN 1076055-04-3 ZCAPLUS
CN Piperazine, 1-cyclopentyl-4-[[1-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1076055-05-4 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-3-(2-furanyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)



RN 1076055-06-5 ZCAPLUS
CN Ethanol, 2-[[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]amino]- (CA INDEX NAME)



RN 1076055-07-6 ZCAPLUS
CN Morpholine, 4-[[1-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 1076055-08-7 ZCAPLUS
CN Piperazine, 1-[[1-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1076055-10-1 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, N,N-diethyl-3-(2-furanyl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)- (CA INDEX NAME)



RN 1076055-12-3 ZCAPLUS
CN Morpholine, 4-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1076055-13-4 ZCAPLUS
CN 1H-1,4-Diazepine, 1-[[1-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]hexahydro-4-methyl- (CA INDEX NAME)

L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1076055-14-5 ZCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[1-(3'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1076055-18-9 ZCAPLUS
CN Piperazine, 1-[[3-(2-furanyl)-1-[4-(3-thienyl)phenyl]-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)



RN 1076055-22-5 ZCAPLUS
CN 1H-1,4-Diazepine, 1-[[1-(3'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]hexahydro-4-methyl- (CA INDEX NAME)

L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
4-yl]methyl]- (CA INDEX NAME)



RN 1076055-29-2 ZCAPLUS
CN Morpholine, 4-[[1-(3'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1076055-30-5 ZCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[1-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1076055-31-6 ZCAPLUS
CN Ethanol, 2-[[[1-(3'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]amino]- (CA INDEX NAME)

L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1076055-24-7 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1076055-25-8 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, N,N-diethyl-1-(3'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)- (CA INDEX NAME)



RN 1076055-26-9 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 3-(2-furanyl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)



RN 1076055-28-1 ZCAPLUS
CN Piperazine, 1-[[1-(3'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-

L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1076055-35-0 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)



RN 1076055-36-1 ZCAPLUS
CN Piperazine, 1-[[1-[4-(1,3-benzodioxol-5-yl)phenyl]-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)



RN 1076055-37-2 ZCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl]-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1076055-39-4 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[1-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



IT **774610-86-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)
RN 774610-86-5 ZCAPLUS
CN Piperazine, 1-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)



L34 ANSWER 2 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2004:841775 ZCAPLUS
DN 141:350163
TI Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists
IN Schiemann, Kai; Ackermann, Karl-August; Arlt, Michael; Finsinger, Dirk; Schadt, Oliver; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PA Merck Patent GmbH, Germany
SO Ger. Offen., 102 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE----10315572	A1	20041014	2003DE-100015572	20030405 <--
AU--2004228120	A1	20041021	2004AU-000228120	20040308 <--
CA-----2521201	A1	20041021	2004CA-002521201	20040308 <--
WO--2004089931	A1	20041021	2004WO-EP002353	20040308 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP-----1626967	A1	20060222	2004EP-000718277	20040308 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR--2004009164	A	20060411	2004BR-000009164	20040308 <--
CN-----1768051	A	20060503	2004CN-080008572	20040308 <--
JP--2006522035	T	20060928	2006JP-000504584	20040308 <--
US-20060264419	A1	20061123	2005US-000552065	20051005 <--
ZA--2005008948	A	20070328	2005ZA-000008948	20051104 <--
PRAI 2003DE-100015572	A	20030405 <--		
2004WO-EP002353	W	20040308 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:350163
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Preparation of title compds. I [X = CH, N; R1 = H, halo, (CH2)nHet, etc.; R2 = (CH2)nHet, (CH2)nAr, cycloalkyl, etc.; R3, R4 = H, (CH2)nCOHet, CHO, etc.; n = 0-5; Ar = (un)substituted Ph; Het = (un)substituted monoarom., bicyclic-heterocycle] and their pharmaceutically acceptable salts were prepared For example, sodium triacetoxyborohydride meditated reductive amination of 1-methyl-piperazine and aldenyde II, e.g., prepared from 2-fluoro-α,γ-dioxo-benzenebutanoic Et ester in 4-steps, afforded the dihydrochloride salt of arylpyrazole III. In 5-HT2A receptor binding assays, 167-examples of compds. I exhibited IC50 values ranging from 0.015-4.7x10-7M. Compds. I are claimed suitable as ligands of 5-HT receptors.

IT

1073627-02-7	**1073627-03-8**	**1073627-08-3**
1073627-11-8	**1073627-12-9**	**1073627-14-1**
1073627-15-2	**1073627-17-4**	**1073627-18-5**
1073627-21-0	**1073627-22-1**	**1073627-25-4**
1073627-26-5	**1073627-49-2**	**1073627-74-3**
1073627-75-4	**1073628-34-8**	**1073628-36-0**
1073628-63-3	**1073628-64-4**	**1073629-14-7**
1073629-15-8	**1073638-81-9**	**1073638-82-0**
1073639-09-4	**1073639-36-7**	**1073639-38-9**
1073639-65-2	**1073639-66-3**	**1073639-92-5**
1073639-93-6	**1073640-21-7**	**1073640-22-8**
1073640-47-7	**1073640-48-8**	**1073640-75-1**
1073640-77-3	**1073641-04-9**	**1073641-05-0**
1073641-30-1	**1073641-31-2**	

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)
RN 1073627-02-7 ZCAPLUS
CN 1H-1,4-Diazepine, 1-[[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]methyl]hexahydro- (CA INDEX NAME)



RN 1073627-03-8 ZCAPLUS
CN 1H-1,4-Diazepine, 1-[[1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]hexahydro- (CA INDEX NAME)



RN 1073627-08-3 ZCAPLUS
CN Piperazine, 1-[[1-[1,1'-biphenyl]-4-yl-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)



RN 1073627-11-8 ZCAPLUS
CN Piperazine, 1-[[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073627-12-9 ZCAPLUS
CN Piperazine, 1-[[1-(6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)



RN 1073627-14-1 ZCAPLUS
CN 1-Piperazinamine, N-[[1-[1,1'-biphenyl]-4-yl-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)



L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073627-21-0 ZCAPLUS
CN Morpholine, 4-[2-[1-[1,1'-biphenyl]-4-yl-5-(2-furanyl)-1H-pyrazol-4-yl]ethyl]- (CA INDEX NAME)



RN 1073627-22-1 ZCAPLUS
CN Morpholine, 4-[2-[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]ethyl]- (CA INDEX NAME)



RN 1073627-25-4 ZCAPLUS
CN Morpholine, 4-[2-[1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]ethyl]- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 1073627-15-2 ZCAPLUS
CN 1-Piperazinamine, N-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)



RN 1073627-17-4 ZCAPLUS
CN 1-Piperazinamine, N-[[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)



RN 1073627-18-5 ZCAPLUS
CN 1-Piperazinamine, N-[[1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073627-26-5 ZCAPLUS
CN Morpholine, 4-[2-[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]ethyl]- (CA INDEX NAME)



RN 1073627-49-2 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-[1,1'-biphenyl]-4-yl-5-(2-furanyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)



RN 1073627-74-3 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 5-(2-furanyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)-1-(6-phenyl-3-pyridinyl)- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073627-75-4 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1073628-34-8 ZCAPLUS
CN 1,2-Ethanediamine, N1-[[1-[1,1'-biphenyl]-4-yl-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073629-14-7 ZCAPLUS
CN Ethanol, 2-[[[1-[1,1'-biphenyl]-4-yl-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]amino]- (CA INDEX NAME)



RN 1073629-15-8 ZCAPLUS
CN Ethanol, 2-[[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]amino]- (CA INDEX NAME)



RN 1073638-81-9 ZCAPLUS
CN Ethanol, 2-[[[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]methyl]amino]- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073628-36-0 ZCAPLUS
CN 1,2-Ethanediamine, N1-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1073628-63-3 ZCAPLUS
CN 1,2-Ethanediamine, N1-[[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1073628-64-4 ZCAPLUS
CN 1,2-Ethanediamine, N1-[[1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073638-82-0 ZCAPLUS
CN Ethanol, 2-[[[1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]amino]- (CA INDEX NAME)



RN 1073639-09-4 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-[1,1'-biphenyl]-4-yl-5-(2-furanyl)-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 1073639-36-7 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 5-(2-furanyl)-N-(2-methoxyethyl)-1-(6-phenyl-3-pyridinyl)- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073639-38-9 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 1073639-65-2 ZCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1073639-66-3 ZCAPLUS
CN Ethanol, 2-[[[1-[1,1'-biphenyl]-4-yl-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]methylamino]- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073639-92-5 ZCAPLUS
CN Ethanol, 2-[[[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]methyl]methylamino]- (CA INDEX NAME)



RN 1073639-93-6 ZCAPLUS
CN Ethanol, 2-[[[1-(6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]methylamino]- (CA INDEX NAME)



RN 1073640-21-7 ZCAPLUS
CN Morpholine, 4-[3-[1-[1,1'-biphenyl]-4-yl-5-(2-furanyl)-1H-pyrazol-4-yl]-2-propen-1-yl]- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073640-22-8 ZCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1073640-47-7 ZCAPLUS
CN Morpholine, 4-[3-[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]-2-propen-1-yl]- (CA INDEX NAME)



RN 1073640-48-8 ZCAPLUS
CN Morpholine, 4-[3-[1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-pyrazol-4-yl]-2-propen-1-yl]- (CA INDEX NAME)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1073640-75-1 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[1-[1,1'-biphenyl]-4-yl-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1073640-77-3 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl]-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1073641-04-9 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[5-(2-furanyl)-1-(6-phenyl-3-pyridinyl)-1H-pyrazol-4-yl]methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1073641-05-0 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[1-[6-(4-fluorophenyl)-3-pyridinyl]-5-(2-furanyl)-1H-

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT **774583-85-6P** **774585-51-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists)
RN 774583-85-6 ZCAPLUS
CN Piperazine, 1-[[5-(2-furanyl)-1-[4-(3-thienyl)phenyl]-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)



RN 774585-51-2 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, N-cyclopropyl-1-(4'-fluoro[1,1'-biphenyl]-4-yl)-N-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-5-(2-furanyl)- (CA INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L34 ANSWER 3 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
pyrazol-4-yl]methyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 1073641-30-1 ZCAPLUS
CN 1H-1,4-Diazepine, 1-[[1-[1,1'-biphenyl]-4-yl-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]hexahydro- (CA INDEX NAME)



RN 1073641-31-2 ZCAPLUS
CN 1H-1,4-Diazepine, 1-[[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]hexahydro- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2004:841774 ZCAPLUS
DN 141:332187
TI Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists.
IN Schadt, Oliver; Schiemann, Kai; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PA Merck Patent GmbH, Germany
SO Ger. Offen., 24 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE----10315571	A1	20041014	2003DE-100015571	20030405 <--
	AU--2004228119	A1	20041021	2004AU-000228119	20040308 <--
	CA-----2521199	A1	20041021	2004CA-002521199	20040308 <--
	WO--2004089888	A1	20041021	2004WO-EP0002352	20040308 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP-----1611094	A1	20060104	2004EP-000718288	20040308 <--
	EP-----1611094	B1	20070620		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LI, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR--2004009160	A	20060502	2004BR-000009160	20040308 <--
	CN-----1768053	A	20060503	2004CN-080008604	20040308 <--
	JP--2006523626	T	20061019	2006JP-000504583	20040308 <--
	AT------365161	T	20070715	2004AT-000718288	20040308 <--
	ES------2287707	T3	20071216	2004ES-000718288	20040308 <--
	US--20060276650	A1	20061207	2005US-000551905	20051005 <--
	ZA--2005008946	A	20070228	2005ZA-000008946	20051104 <--
PRAI	2003DE-100015571	A	20030405	<--	
	2004WO-EP0002352	W	20040308	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:332187
GI



AB Title compds. [I; R2, R4 = H, A, halo, cycloalkyl, CF3, NO2, cyano, OCF3, OA, NHA, NA2, NH2; R3, R6 = (CH2)nHet, (CH2)nAr; R1 = H, organic residue; A = alkyl, alkoxy, alkenyl, alkenyloxyalkyl; Het = (substituted) (unsatd.) mono- or bicyclic heterocyclyl, heteroatom-containing organic residue; Ar = (substituted) Ph; n = 0-5; X undefined], were claimed (no synthetic or biol. data).
IT **1070643-43-4** **1070643-44-5** **1070643-56-9**
1070643-57-0 **1070643-58-1** **1070643-59-2**
1070643-60-5 **1070643-61-6** **1070643-62-7**
1070643-63-8 **1070643-64-9** **1070643-65-0**
1070643-66-1 **1070643-67-2** **1070643-68-3**
1070643-69-4 **1070643-70-7** **1070643-71-8**
1070643-72-9 **1070643-73-0** **1070643-74-1**
1070643-75-2 **1070643-76-3** **1070643-80-9**
1070643-81-0
RL: PRPH (Prophetic)
(Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
receptor antagonists.)
RN 1070643-43-4 ZCAPLUS
CN Piperazine, 1-ethyl-4-[[5-[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-1H-pyrazol-5-yl]-2-furanyl]methyl]- (CA INDEX NAME)



RN 1070643-44-5 ZCAPLUS
CN 2-Furanmethanamine, N-ethyl-5-[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-1H-pyrazol-5-yl]-N-methyl- (CA INDEX NAME)



RN 1070643-56-9 ZCAPLUS
CN Piperazine, 1-[[1-(4'-fluoro-2-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1070643-57-0 ZCAPLUS
CN Piperazine, 1-ethyl-4-[[1-(4'-fluoro-2-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1070643-58-1 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, N-ethyl-1-(4'-fluoro-2-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-N-methyl- (CA INDEX NAME)



RN 1070643-59-2 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[1-(4'-fluoro-2-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1070643-60-5 ZCAPLUS
CN Piperazine, 1-[[1-(2-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)



RN 1070643-61-6 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[1-(2-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1070643-62-7 ZCAPLUS
CN Piperazine, 1-[[1-(2-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-ethyl- (CA INDEX NAME)



RN 1070643-63-8 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-(2-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-N-ethyl-5-(2-furanyl)-N-methyl- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1070643-64-9 ZCAPLUS
CN Piperazine, 1-[[1-(4'-fluoro-3-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)



RN 1070643-65-0 ZCAPLUS
CN Piperazine, 1-ethyl-4-[[1-(4'-fluoro-3-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1070643-66-1 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[1-(4'-fluoro-3-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1070643-69-4 ZCAPLUS
CN Piperazine, 1-[[1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-ethyl- (CA INDEX NAME)



RN 1070643-70-7 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

PAGE 1-A



L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1070643-67-2 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, N-ethyl-1-(4'-fluoro-3-methyl[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-N-methyl- (CA INDEX NAME)



RN 1070643-68-3 ZCAPLUS
CN Piperazine, 1-[[1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A

RN 1070643-71-8 ZCAPLUS
CN Piperazine, 1-[[1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1070643-72-9 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-N,N-dimethyl- (CA INDEX NAME)



RN 1070643-73-0 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-N-ethyl-5-(2-furanyl)-N-methyl- (CA INDEX NAME)



RN 1070643-74-1 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-(3,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1070643-75-2 ZCAPLUS
CN Piperazine, 1-[[1-(2,4'-difluoro[1,1'-biphenyl]-4-yl)-5-(2-furanyl)-1H-pyrazol-4-yl]methyl]-4-methyl- (CA INDEX NAME)



RN 1070643-76-3 ZCAPLUS
CN 1H-Pyrazole-4-methanamine, 1-(2,4'-difluoro[1,1'-biphenyl]-4-yl)-N-ethyl-5-(2-furanyl)-N-methyl- (CA INDEX NAME)

L34 ANSWER 4 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1070643-80-9 ZCAPLUS
CN Piperazine, 1-[[5-[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-1H-pyrazol-5-yl]-2-furanyl]methyl]-4-methyl- (CA INDEX NAME)



RN 1070643-81-0 ZCAPLUS
CN 3-Pyrrolidinol, 1-[[5-[1-(4'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-1H-pyrazol-5-yl]-2-furanyl]methyl]- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L34 ANSWER 5 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2004:40643 ZCAPLUS
DN 140:391231
TI Novel 3,3a,4,5,6,7-hexahydroindazole and arylthiazolylpyrazoline derivatives as anti-inflammatory agents
AU Nasr, Magda N. A.; Said, Shenta A.
CS Department of Pharmaceutical Organic Chemistry, College of Pharmacy, University of Mansoura, Mansoura, Egypt
SO Archiv der Pharmazie (Weinheim, Germany) (**2003**), 336(12), 551-559
CODEN: ARPMAS; ISSN: 0365-6233
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
OS CASREACT 140:391231
AB A novel series of 7-benzylidene-3,3a,4,5,6,7-hexahydro-3-phenyl-2H-indazole substituted at the 2-position were synthesized. The reaction of 2,6-bis-benzylidenecyclohexanone (1) with thiosemicarbazide in the presence of NaOH afforded a mixture of the 3-H, 3a-H trans (2) and cis (2a) diastereoisomers which have been separated by fractional recrystn. Interaction of the first intermediate (2) with substituted phenacyl bromides, aromatic aldehydes and chloroacetic acid in presence of a mixture of acetic acid and acetic anhydride, and 2,3-dichloroquinoxaline yielded the corresponding 7-benzylidene-3,3a,4,5,6,7-hexahydro-3-phenyl-2H-indazole derivs. substituted at the 2-position with 4-aryl-2-thiazolyl (3a, b), 5-arylidene-4,5-dihydro-4-oxo-2-thiazolyl (4a, b) and thiazolo[4,5-b]quinoxalin-2-yl (5), resp. The other intermediates, 3,5-diaryl-1-thiocarbamoyl-2-pyrazolines (7a-d), interacted with the previously-mentioned reagents to produce 3,5-diaryl-1-(4-aryl-2-thiazolyl)-2-pyrazolines (8a-h), 3,5-diaryl-1-(5-arylidene-4,5-dihydro-4-oxo-2-thiazolyl)-2-pyrazolines (9a-d) and 3,5-diaryl-1-(thiazolo[4,5-b]quinoxalin-2-yl)-2-pyrazoline derivs. (10a, b), resp. Some of the newly prepared compds. were evaluated for their anti-inflammatory activity. The structures of the new compds. were confirmed by elemental anal. as well as 1H-NMR, IR, and MS.
IT **686725-88-2P** **686725-92-8P**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel 3,3a,4,5,6,7-hexahydroindazole and arylthiazolylpyrazoline derivs. as anti-inflammatory agents)
RN 686725-88-2 ZCAPLUS
CN Thiazole, 4-(4-chlorophenyl)-2-[3-(4-chlorophenyl)-5-(2-furanyl)-4,5-dihydro-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 686725-92-8 ZCAPLUS
CN Thiazole, 4-(4-chlorophenyl)-2-[5-(2-furanyl)-4,5-dihydro-3-(4-methylphenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



IT **686726-02-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L34 ANSWER 5 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel 3,3a,4,5,6,7-hexahydroindazole and arylthiazolylpyrazoline derivs. as anti-inflammatory agents)
RN 686726-02-3 ZCAPLUS
CN 4(5H)-Thiazolone, 5-[(4-chlorophenyl)methylene]-2-[5-(2-furanyl)-4,5-dihydro-3-(4-methylphenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



IT **686725-82-6P** **686725-84-8P** **686725-86-0P**
686725-90-6P **686725-98-4P** **686726-00-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(novel 3,3a,4,5,6,7-hexahydroindazole and arylthiazolylpyrazoline derivs. as anti-inflammatory agents)
RN 686725-82-6 ZCAPLUS
CN Thiazole, 4-(4-bromophenyl)-2-[3-(4-bromophenyl)-5-(2-furanyl)-4,5-dihydro-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 686725-84-8 ZCAPLUS
CN Thiazole, 2-[3-(4-bromophenyl)-5-(2-furanyl)-4,5-dihydro-1H-pyrazol-1-yl]-4-(4-chlorophenyl)- (CA INDEX NAME)



RN 686725-86-0 ZCAPLUS
CN Thiazole, 4-(4-bromophenyl)-2-[3-(4-chlorophenyl)-5-(2-furanyl)-4,5-dihydro-1H-pyrazol-1-yl]- (CA INDEX NAME)

L34 ANSWER 5 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 686725-90-6 ZCAPLUS
CN Thiazole, 4-(4-bromophenyl)-2-[5-(2-furanyl)-4,5-dihydro-3-(4-methylphenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 686725-98-4 ZCAPLUS
CN 4(5H)-Thiazolone, 2-[3-(4-bromophenyl)-5-(2-furanyl)-4,5-dihydro-1H-pyrazol-1-yl]-5-[(4-bromophenyl)methylene]- (CA INDEX NAME)



RN 686726-00-1 ZCAPLUS
CN 4(5H)-Thiazolone, 2-[3-(4-bromophenyl)-5-(2-furanyl)-4,5-dihydro-1H-pyrazol-1-yl]-5-[(4-chlorophenyl)methylene]- (CA INDEX NAME)



OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 6 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2003:971725 ZCAPLUS
DN 140:35893
TI Transcription factor modulating compounds and methods of use thereof
IN Levy, Stuart B.; Alekshun, Michael N.; Podlogar, Brent L.; Ohemeng, Kwasi; Verma, Atul K.; Warchol, Tadeusz; Bhatia, Beena
PA USA
SO U.S. Pat. Appl. Publ., 301 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US-20030229065	A1	20031211	2002US-000139591	20020814 <--
	CA-----2445515	A1	20021104	2002CA-002445515	20020506 <--
	WO--2004001058	A2	20031231	2002WO-US00014255	20020506 <--
	WO--2004001058	A3	20050303		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU--2002367953	A1	20040106	2002AU-000367953	20020506 <--
	AU--2002367953	B2	20080717		
	EP-----1524974	A2	20050427	2002EP-000807554	20020506 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP--2005519998	T	20050707	2004JP-000515557	20020506 <--
	US-20050124678	A1	20050609	2003US-000700661	20031103 <--
	US-----7405235	B2	20080729		
	US-20090131401	A1	20090521	2008US-000069723	20080212 <--
	AU--2008203017	A1	20080731	2008AU-000203017	20080708 <--
PRAI	2001US-00288660P	P	20010504	<--	
	2002AU-000367953	A3	20020506	<--	
	2002WO-US0014255	W	20020506	<--	
	2002US-000139591	A2	20020814	<--	
	2002US-00423319P	P	20021101	<--	
	2002US-00425916P	P	20021113	<--	
	2003US-000700661	A3	20031103	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 140:35893
AB Methods for identifying compound useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. In one embodiment, the method comprises contacting a microbial cell comprising: (1) a selectable marker under the control of a transcription factor responsive element and (2) a transcription factor, with a compound under conditions which allow interaction of the compound with the microbial cell; and measuring the ability of the compound to affect the growth or survival of the microbial cell as an indication of whether the test compound modulates the activity of a transcription factor.
IT **634189-97-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining marker under control of responsive element)
RN 634189-97-2 ZCAPLUS
CN Morpholine, 4-[[4-[2-[5-(2-furanyl)-4,5-dihydro-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]-4-thiazolyl]phenyl]sulfonyl]-, hydrobromide (1:1) (CA INDEX NAME)

L34 ANSWER 5 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

L34 ANSWER 6 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L34 ANSWER 7 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2003:301077 ZCAPLUS
DN 138:304309
TI Preparation of 2-(heterocyclylalkyl)-1,2,3,4-tetrahydroquinolines and analogs as 5-HT1A receptor inhibitors for treatment of urinary tract disorders
IN Leonardi, Amedeo; Motta, Gianni; Riva, Carlo; Testa, Rodolfo; Corbett, Jeff W.
PA Recordati S.A., Switz.; Recordati Industria Chimica e Farmaceutica S.p.A.
SO PCT Int. Appl., 212 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2003031436	A1	20030417	2002WO-EP011282	20021007 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IT--20011MI2060	A1	20030407	2001IT-MI0002060	20011005 <--
	CA-----2458456	A1	20030417	2002CA-002458456	20021007 <--
	AU--2002346979	A1	20030422	2002AU-000346979	20021007 <--
	AU--2002346979	B2	20050929		
	AU--2002346979	B9	20060302		
	US-20030162777	A1	20030828	2002US-000266104	20021007 <--
	US-20030181446	A1	20030925	2002US-000266088	20021007 <--
	EP-----1432701	A1	20040630	2002EP-000782863	20021007 <--
	EP-----1432701	B1	20051221		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR--2002013067	A	20040928	2002BR-000013067	20021007 <--
	HU--2004001598	A2	20041228	2004HU-000001598	20021007 <--
	CN-----1564820	A	20050112	2002CN-000819728	20021007 <--
	JP--2005508952	T	20050407	2003JP-000534419	20021007 <--
	NZ------532511	A	20051028	2002NZ-000532511	20021007 <--
	AT------313540	T	20060115	2002AT-000782863	20021007 <--
	ES-----2253568	T3	20060601	2002ES-000782863	20021007 <--
	AP--------1705	A	20070228	2004AP-000002997	20021007 <--
	IN---200400392	A	20060414	2004IN-000000392	20040324 <--
	MX---2004002962	A	20050620	2004MX-000002962	20040330 <--
	NO---2004001833	A	20040705	2004NO-000001833	20040504 <--
	ZA---2004003356	A	20041108	2004ZA-000003356	20040504 <--
	HK-----1067362	A1	20060804	2004HK-000107812	20041011 <--
PRAI	2001IT-MI0002060	A	20011005	<--	
	2002US-00350680P	P	20020122	<--	
	2002WO-EP011282	W	20021007	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 138:304309
GI

L34 ANSWER 7 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 7 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



I



II

AB Title compds. I [wherein R1 = H, halo, OH, (halo)alkyl, (halo)alkoxy, NO2, NR3R4, or (un)substituted Ph or heterocyclyl; R2 = 1 or 2 substituents selected from H or alkyl; R3 and R4 = independently H, alkyl, acyl, or alkoxycarbonyl; Y = a bond or CH2; Q = CO, CS, or SO2; A = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, aryl, heterocyclyl, (di)alkylamino, arylamino, or arylalkylamino; n = 1 or 2; X = (un)substituted piperidinyl or piperazinyl; Z = a bond, O, S, CH2, CH2CH2, CO, CHOH, OCH2, NH, NHCO, or NHCONHCH2; or ZB = 2,3-dihydrobenzo[1,4]dioxin-2-yl; B = (un)substituted monocyclic or bicyclic (hetero)aryl; with provisos; and enantiomers, diastereomers, N-oxides, crystalline forms, hydrates, solvates, or pharmaceutically acceptable salts thereof] were prepared as serotonergic receptor antagonists. For example, coupling of 2-chloromethylquinoline with 1-(4-indolyl)piperazine in the presence of DIPEA in DMF gave 1-(4-indolyl)-4-(quinolin-2-ylmethyl)piperazine (70%), which was hydrogenated using PtO2/AcOH/H2 to provide the tetrahydroquinoline derivative (76.5%). Amidation with cyclohexanecarbonyl chloride in the presence of TEA in CH2Cl2 afforded II (81%). The (+)- and (-)-enantiomers were separated via chiral column chromatog. II inhibited the human 5HT1A-serotonergic receptor in transfected HeLa cells with Ki of 3.3 nM, while (+)-II showed a binding affinity with Ki of 0.2 nM. Similarly, (+)-II proved more effective than II in suppressing the frequency of rhythmic bladder-voiding contractions in rats with ED50 values of 24 μg/kg and 64 μg/kg, resp. In addition, (+)-II exhibited significant and long-lasting post-synaptic 5-HT1A-receptor antagonist activity by suppressing forepaw treading induced by 8-OH-DPAT in rats with 100% inhibition after 0.5 h and 98% inhibition after 4 h of administration of a dose of 1 mg/kg p.o. By contrast, (-)-II showed only 19% inhibition after 0.5 h and 5% inhibition after 4 h of administration of a dose of 1 mg/kg p.o.
IT **511233-54-8P**, 1-[1-(Cyclohexylcarbonyl)-1,2,3,4-tetrahydroquinolin-2-ylmethyl]-4-[5-(2-furyl)-2H-3-pyrazolyl]piperidine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(5-HT1A antagonist; preparation of (aminoalkyl)- and (heterocyclylalkyl)tetrahydroquinoline 5-HT1A antagonists from haloalkylquinolines and amines or heterocycles for treatment of urinary tract and CNS disorders)
RN 511233-54-8 ZCAPLUS
CN Methanone, cyclohexyl[2-[[4-[5-(2-furanyl)-1H-pyrazol-1-yl]-1-piperidinyl]methyl]-3,4-dihydro-1(2H)-quinolinyl]- (CA INDEX NAME)

L34 ANSWER 8 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2002:438220 ZCAPLUS
DN 137:384785
TI The regioselectivity of the formation of 2-pyrazolylthiazoles and their precursors from the reaction of 2-hydrazinothiazoles with 4,4,4-trifluoro-1-hetaryl-1,3-butanediones
AU Denisova, Anna B.; Sosnovskikh, Vyacheslav Ya.; Dehaen, Wim; Toppet, Suzanne; Van Meervelt, Luc; Bakulev, Vasilly A.
CS Toslab, The Urals State Technical University, Yekaterinburg, 620002, Russia
SO Journal of Fluorine Chemistry (**2002**), 115(2), 183-192
CODEN: JFLCAR; ISSN: 0022-1139
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 137:384785
GI



I

AB Reaction of 2-hydrazinothiazoles with 1-thienyl- and 1-furyl-1,3-butanediones in methanol in the presence of hydrochloric acid mainly leads to a mixture of pyrazoles and pyrazolines in strong acidic conditions. Isomeric hydrazones and pyrazolines were formed and isolated in these reactions in the absence of hydrochloric acid. It has been shown that the regioselectivity in the reaction of diketones with 2-hydrazinothiazoles is governed by both the concentration of acid and the nature of substituents in the 1,3-diketones. Cyclization of hydrazones is shown to occur under milder conditions than dehydration for pyrazolines. The new heterocyclic compds. were prepared and fully characterized by NMR spectra and by X-ray anal. for I.
IT **476172-22-2P** **476172-23-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(regioselective preparation of 2-pyrazolylthiazoles from the condensation of 2-hydrazinothiazoles with 4,4,4-trifluoro-1-hetaryl-1,3-butanediones)
RN 476172-22-2 ZCAPLUS
CN 1H-Pyrazol-5-ol, 1-[4-(4-chlorophenyl)-2-thiazolyl]-3-(2-furanyl)-4,5-dihydro-5-(trifluoromethyl)- (CA INDEX NAME)



RN 476172-23-3 ZCAPLUS
CN 1H-Pyrazol-5-ol, 3-(2-furanyl)-4,5-dihydro-1-(4-phenyl-2-thiazolyl)-5-(trifluoromethyl)- (CA INDEX NAME)



L34 ANSWER 8 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
IT **476172-15-3P** **476172-16-4P** **476172-28-8P**
476172-31-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(regioselective preparation of 2-pyrazolylthiazoles from the condensation of 2-hydrazinothiazoles with 4,4,4-trifluoro-1-hetaryl-1,3-butanediones)
RN 476172-15-3 ZCAPLUS
CN Thiazole, 4-(4-chlorophenyl)-2-[5-(2-furanyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 476172-16-4 ZCAPLUS
CN Thiazole, 2-[5-(2-furanyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-4-phenyl- (CA INDEX NAME)



RN 476172-28-8 ZCAPLUS
CN Thiazole, 4-(4-chlorophenyl)-2-[3-(2-furanyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 476172-31-3 ZCAPLUS
CN Thiazole, 2-[3-(2-furanyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]-4-phenyl- (CA INDEX NAME)



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 9 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 1992:625143 ZCAPLUS
DN 117:225143
OREF 117:38659a,38662a
TI Studies on the complexes of rare earths with sulfur-containing organic ligands. IV. Synthesis and characterization of solid complexes of light rare earths with 3-phenyl-5-(fur-2-yl)pyrazolinedithioformate
AU Zhang, Weiguang; Tang, Ning; Gan, Xinmin; Tan, Minyu
CS Dep. Chem., Jiangxi Norm. Univ., Peop. Rep. China
SO Yingyong Huaxue (**1992**), 9(3), 83-6
CODEN: YIHUED; ISSN: 1000-0518
DT Journal
LA Chinese
AB LnL3.nH2O (Ln = La, Pr, Nd, Sm, Eu; HL = 3-phenyl-5-(fur-2-yl)pyrazolinedithioformic acid; n = 2, 4) were prepared and characterized by elemental anal., IR spectra, molar conductance, thermal anal. and fluorescence spectra. L is coordinated through the 2 S atoms.
IT **144395-32-4P** **144395-34-6P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and IR spectrum of)
RN 144395-32-4 ZCAPLUS
CN Lanthanum, tris[5-(2-furanyl)-4,5-dihydro-3-phenyl-1H-pyrazole-1-carbodithioato-S,S']-, tetrahydrate, (OC-6-11)- (9CI) (CA INDEX NAME)



RN 144395-34-6 ZCAPLUS
CN Neodymium, tris[5-(2-furanyl)-4,5-dihydro-3-phenyl-1H-pyrazole-1-carbodithioato-S,S']-, tetrahydrate, (OC-6-11)- (9CI) (CA INDEX NAME)

L34 ANSWER 9 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT **144395-33-5P** **144395-35-7P** **144423-48-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and fluorescence and IR spectra of)
RN 144395-33-5 ZCAPLUS
CN Praseodymium, tris[5-(2-furanyl)-4,5-dihydro-3-phenyl-1H-pyrazole-1-carbodithioato-S,S']-, tetrahydrate, (OC-6-11)- (9CI) (CA INDEX NAME)



RN 144395-35-7 ZCAPLUS
CN Samarium, tris[5-(2-furanyl)-4,5-dihydro-3-phenyl-1H-pyrazole-1-carbodithioato-S,S']-, dihydrate, (OC-6-11)- (9CI) (CA INDEX NAME)

L34 ANSWER 9 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 144423-48-3 ZCAPLUS
CN Europium, tris[5-(2-furanyl)-4,5-dihydro-3-phenyl-1H-pyrazole-1-carbodithioato-S,S']-, tetrahydrate, (OC-6-11)- (9CI) (CA INDEX NAME)



L34 ANSWER 10 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 1985:6328 ZCAPLUS
DN 102:6328
OREF 102:1147a,1150a
TI Syntheses and biological activity of heterocycles derived from 4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]benzoic acid
AU Varma, K. S.; Fernandez, P. S.
CS Dep. Chem., St. Xavier's Coll., Bombay, 400 001, India
SO Journal of the Indian Chemical Society (**1984**), 61(3), 234-6
CODEN: JICSAH; ISSN: 0019-4522
DI Journal
LA English
OS CASREACT 102:6328
GI



AB A series of new compds. I (R = CO2H, CONHNH2, CONHN:CHR1, CONHNHCSNHC6H4R-4, R3, R4; R1 = Ph, 4-MeC6H4, 2-HOC6H4, 4-MeOC6H4, 2-furyl; R2 = H, Me, Cl, OMe) have been synthesized and some of the compds. have been screened against a few microorganisms for antibacterial activity.
IT **93606-89-4P** **93606-90-7P** **93606-91-8P**
93606-92-9P **93606-93-0P** **93606-94-1P**
93606-95-2P **93606-96-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)
RN 93606-89-4 ZCAPLUS
CN 3H-1,2,4-Triazole-3-thione, 5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]-2,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 93606-90-7 ZCAPLUS
CN 3H-1,2,4-Triazole-3-thione, 5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]-2,4-dihydro-4-(4-methylphenyl)- (CA INDEX NAME)

L34 ANSWER 10 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 93606-91-8 ZCAPLUS
CN 3H-1,2,4-Triazole-3-thione, 4-(4-chlorophenyl)-5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]-2,4-dihydro- (CA INDEX NAME)



RN 93606-92-9 ZCAPLUS
CN 3H-1,2,4-Triazole-3-thione, 5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]-2,4-dihydro-4-(4-methoxyphenyl)- (CA INDEX NAME)



RN 93606-93-0 ZCAPLUS
CN 1,3,4-Oxadiazol-2-amine, 5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]-N-phenyl- (CA INDEX NAME)



RN 93606-94-1 ZCAPLUS
CN 1,3,4-Oxadiazol-2-amine, 5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]-N-(4-methylphenyl)- (CA INDEX NAME)

L34 ANSWER 10 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 93606-95-2 ZCAPLUS
CN 1,3,4-Oxadiazol-2-amine, N-(4-chlorophenyl)-5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]- (CA INDEX NAME)



RN 93606-96-3 ZCAPLUS
CN 1,3,4-Oxadiazol-2-amine, 5-[4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]phenyl]-N-(4-methoxyphenyl)- (CA INDEX NAME)



L34 ANSWER 11 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 1977:105229 ZCAPLUS
DN 86:105229
OREF 86:16597a,16600a
TI Electrochemical behavior of N-aryl-Δ2-pyrazolines. IX. Structure effects in the spectra of radical cations and dications of monomers and dimers of N-aryl-Δ2-pyrazolines and mechanism of the Knorr-pyrazoline test
AU Pragst, F.; Vieth, B.
CS Sekt. Chem., Humboldt-Univ. Berlin, Berlin, Ger. Dem. Rep.
SO Zeitschrift fuer Physikalische Chemie (Leipzig) (**1976**), 257(5), 849-67
CODEN: ZPCLAH; ISSN: 0323-4479
DI Journal
LA German
GI



AB A bathochromic shift of the first UV bond for cation radicals of I (R = H, MeO, Me, Ph, Cl, NO2; R1, R2 = aryl, alkyl) was rationalized in terms of electronic and steric effects. The cation radicals of II, III (R1, R2 as above), and IV are violene types and absorb at very long wavelengths. Oxidation of I by FeCl3 or NaNO2 in concentrated H2SO4 yields dications of the corresponding dimers (II) in agreement with electrochem. oxidation data.
IT **61979-54-2** **61987-61-9**
RL: PRP (Properties)
(UV spectrum of)
RN 61979-54-2 ZCAPLUS
CN 1H-Pyrazolium, 5-(2-furanyl)-1-[4-[4-[5-(2-furanyl)-4,5-dihydro-3-(4-methylphenyl)-1H-pyrazolium-1-ylidene]-2,5-cyclohexadien-1-ylidene]-2,5-cyclohexadien-1-ylidene]-4,5-dihydro-3-(4-methylphenyl)- (CA INDEX NAME)



RN 61987-61-9 ZCAPLUS
CN 1H-Pyrazole, 1,1'-[1,1'-biphenyl]-4,4'-diylbis[5-(2-furanyl)-4,5-dihydro-3-(4-methylphenyl)-, radical ion(1+) (9CI) (CA INDEX NAME)

L34 ANSWER 11 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L34 ANSWER 12 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 1975:461730 ZCAPLUS
DN 83:61730
OREF 83:9753a,9756a
TI 4-(3-Aryl-1-pyrazolyl)stilbene fluorescent whiteners
IN Haeusermann, Heinrich; Troxler, Eduard
PA Ciba-Geigy Corp.
SO U.S., 9 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-----3796706	A	19740312	1970US-000065699	19700820 <--
PRAI 1968US-000703865	A2	19680208 <--		

GI For diagram(s), see printed CA Issue.
AB Fluorescent whiteners (I, R = Cl, 3-(2-furyl)-1-pyrazolyl, substituted triazinylamino, substituted stilbenylureido; R1 = H, SO3H; R2 = SO3H CN; R3 = Ph, p-ClC6H4, R4 = H, or (R3R4) = o-C6H4CH2CH2)] were prepared and were used to whiten cellulosic, acetate, polyester, and polyamide fibers and in detergent compns. Thus, 2,4-HO3S(H2NNH)C6H3CH:CHC6H3(NHNH2)SO3H-4,2 in an aqueous NaOH solution was treated with 2-furyl 2-chlorovinyl ketone to give fluorescent whitener I(R = 3-(2-furyl)-1-pyrazolyl, R1 = R2 = SO3Na, R3 = 2-furyl, R4 = H). The other I were similarly prepared
IT **51837-62-8P**
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)
RN 51837-62-8 ZCAPLUS
CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[3-(2-furanyl)-1H-pyrazol-1-yl]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

L34 ANSWER 13 OF 13 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 1969:115058 ZCAPLUS
DN 70:115058
OREF 70:21487a,21490a
TI Fluorinated nitrogen heterocycles via cyclization. III. 3-Trifluoromethyl-1-(4-trifluoromethyl-2-pyridyl)pyrazoles from fluorinated 1,3-diketones and 4-trifluoromethyl-2-hydrazinopyridines
AU Portnoy, Seymour
CS Frankford Arsenal, Philadelphia, PA, USA
SO Journal of Heterocyclic Chemistry (**1969**), 6(2), 223-8
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
AB Fluorinated 1,3-diketone CF3COCH2COR1 underwent cyclization with 4-trifluoromethyl-2-hydrazinopyridines (I) to give a series of 3-trifluoromethyl-1-(4-trifluoromethyl-2-pyridyl)pyrazoles (II). I were prepared by conversion of 4-trifluoromethyl-2-pyridones to the chloropyridines followed by treatment of the latter with hydrazine hydrate.
IT **22122-94-7P** **22123-05-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22122-94-7 ZCAPLUS
CN 1H-Pyrazol-5-ol, 3-(2-furanyl)-4,5-dihydro-1-[6-(2-thienyl)-4-(trifluoromethyl)-2-pyridinyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RN 22123-05-3 ZCAPLUS
CN Pyridine, 2-[5-(2-furanyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-6-phenyl-4-(trifluoromethyl)- (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

```
=> d his


     FILE 'ZCAPLUS' ENTERED AT 12:29:38 ON 05 FEB 2010
L1             1 US20070010531/PN

     FILE 'REGISTRY' ENTERED AT 12:29:58 ON 05 FEB 2010

     FILE 'ZCAPLUS' ENTERED AT 12:29:58 ON 05 FEB 2010
L2             TRA L1 1- RN :      678 TERMS

     FILE 'REGISTRY' ENTERED AT 12:29:58 ON 05 FEB 2010
L3           678 SEA L2
L4           674 L3 AND N2C3/ES
L5           206 L4 AND OC4/ES
L6           206 L5 AND (C6 OR NC5)/ES
L7               STR
L8         59880 OC4/ES AND N2C3/ES AND (C6 OR NC5)/ES
L9            50 L7 SAM SUB=L8
L10        10904 L7 FULL SUB=L8
                 SAV TEM J064C1RCE/A L10
L11          205 L10 AND L3
L12        10699 L10 NOT L11

     FILE 'ZCAPLUS' ENTERED AT 12:35:47 ON 05 FEB 2010
L13            2 L11
L14          698 L12
L15          164 L14 AND (PRD<=20040410 OR AD<=20040410)
L16          456 L14 AND PD<=20030405
L17          422 L14 AND PD<=20020405
L18          126 L15 AND L16-17
L19          330 L16 NOT L18
L20          314 L17 NOT L18
L21           38 L15 NOT L18
                 SEL HIT RN L21

     FILE 'REGISTRY' ENTERED AT 12:41:40 ON 05 FEB 2010
L22          193 E1-193
L23              STR L7
L24           29 L23 SAM SUB=L10
L25          496 L23 FULL SUB=L10
                 SAV TEM J064C1RCES/A L25
L26          204 L25 AND L3
L27          292 L25 NOT L26

     FILE 'ZCAPLUS' ENTERED AT 13:01:30 ON 05 FEB 2010
L28            2 L26
L29            2 L13,L28
L30           25 L27
L31            7 L30 AND (PRD<=20040410 OR AD<=20040410)
L32            9 L30 AND PD<=20030405
L33            6 L30 AND PD<=20020405
L34           13 L31-33

=>
```